secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001628280-22-020108
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics appoints Laura Bessen, M.D. and Donna Grogan, M.D. to board of directors
--------------------------------------------------------------------------------

- Drs. Bessen and Grogan elected as directors effective July 29, 2022; Grogan Class I, Bessen Class II.
- Each granted stock options for 41,200 shares under 2020 plan; one-third vests at year one, remainder quarterly.
- Bessen brings two decades of medical affairs and clinical development expertise; Grogan over 25 years in drug development and regulatory strategy.
- Appointments support C4T's evolution as it advances two clinical-stage programs and prepares additional candidates.
- No reportable related-party transactions or arrangements per Item 404(a) of Regulation S-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828022020108/0001628280-22-020108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828022020108/cccc-20220729.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-020108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer